Skip to main content
SpringerLink
Log in

Central Nervous System

  • Chapter
  • First Online:
Side Effects of Medical Cancer Therapy

  • 1589 Accesses

Abstract

Tumors of the central nervous system (CNS) differ in many ways from other tumors. First, these tumors are separated by an important natural barrier, the blood–brain barrier, with the aim of defending the CNS from external noxa but, in the case of cancer, limiting the efficacy of therapy. Second, the tumors of the CNS are malignant not only because of their biological behavior but because of their localization. Even very small and slow-growing tumors localized at important regions of the brain, like the brainstem, can have serious, deleterious, and fatal impact. Finally, tumors of the CNS have a very important impact on the quality of life of patients, with long-term disabling effects on everyday life. Therefore, tumors of the CNS require early diagnosis and a rapid multidisciplinary approach to choose optimal treatment. In these cases, special attention must be taken to select chemotherapies and targeting agents that do cross the blood–brain barrier.

The focus of this chapter is side effects from chemotherapies used to treat a wide variety of tumors, from gliomas to metastatic (meningeal disease) lesions from other organs. This chapter will discuss the main complications from the treatment of CNS disease (glioma, medulloblastoma, and carcinomatous meningitis), specifically from radiotherapy, from cytotoxic and targeted ­anticancer therapy, and from supportive care measures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51. Epub 10 Nov 2009.

    Article  PubMed  CAS  Google Scholar 

  2. Conill C, Berenguer J, Vargas M, Lopez-Soriano A, Valduvieco I, Marruecos J, et al. Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol. 2007;9(9):590–5. Epub 9 Oct 2007.

    Article  PubMed  CAS  Google Scholar 

  3. Dresemann G. Temozolomide in malignant glioma. Onco Targets Ther. 2010;3:139–46. Epub 22 Sept 2010.

    PubMed  CAS  Google Scholar 

  4. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58(19):4363–7.

    PubMed  CAS  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. Epub 11 Mar 2005.

    Article  PubMed  CAS  Google Scholar 

  6. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051–7.

    Article  PubMed  CAS  Google Scholar 

  7. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88(7):1004–11.

    Article  PubMed  CAS  Google Scholar 

  8. Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol. 2004;15(1):161–71.

    Article  PubMed  CAS  Google Scholar 

  9. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5(3):198–206. Epub 4 May 2005.

    Article  PubMed  CAS  Google Scholar 

  10. Abrey LE, Christodoulou C. Temozolomide for treating brain metastases. Semin Oncol. 2001;28(4 Suppl 13):34–42. Epub 11 Sept 2001.

    Article  PubMed  CAS  Google Scholar 

  11. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19 Pt 1):6767–71.

    Article  PubMed  CAS  Google Scholar 

  12. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375–82. Epub 1 Mar 2002.

    Article  PubMed  CAS  Google Scholar 

  13. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22(4):610–6. Epub 17 Jan 2004.

    Article  PubMed  CAS  Google Scholar 

  14. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 1985;63(2):218–23. Epub 1 Aug 1985.

    Article  PubMed  CAS  Google Scholar 

  15. Katz ME, Glick JH. Nitrosoureas: a reappraisal of clinical trials. Cancer Clin Trials. 1979;2(4):297–316. Epub 1 Jan 1979.

    PubMed  CAS  Google Scholar 

  16. Gutin PH, Wilson CB, Kumar AR, Boldrey EB, Levin V, Powell M, et al. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer. 1975;35(5):1398–404. Epub 1 May 1975.

    Article  PubMed  CAS  Google Scholar 

  17. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer. 2010;10:30. Epub 4 Feb 2010.

    Article  PubMed  Google Scholar 

  18. Block M, Lachowiez RM, Rios C, Hirschl S. Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU. Med Pediatr Oncol. 1990;18(3):256–60. Epub 1 Jan 1990.

    Article  PubMed  CAS  Google Scholar 

  19. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009;102(3):179–87; quiz 87–9, 222. Epub 10 Apr 2009.

    Article  PubMed  Google Scholar 

  20. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther. 1997;62(2):225–9. Epub 1 Aug 1997.

    Article  PubMed  CAS  Google Scholar 

  21. Mahmood T, Mudad R. Pulmonary toxicity secondary to procarbazine. Am J Clin Oncol. 2002;25(2):187–8. Epub 11 Apr 2002.

    Article  PubMed  Google Scholar 

  22. Aydin B, Patil M, Bekele N, Wolff JE. Vincristine in high-grade glioma. Anticancer Res. 2010;30(6):2303–10. Epub 24 July 2010.

    PubMed  CAS  Google Scholar 

  23. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol. 2004;6(4):300–5. Epub 21 Oct 2004.

    Article  PubMed  CAS  Google Scholar 

  24. Qweider M, Gilsbach JM, Rohde V. Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007;6(3):280–3. Epub 16 Mar 2007.

    Article  PubMed  Google Scholar 

  25. Al Ferayan A, Russell NA, Al Wohaibi M, Awada A, Scherman B. Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection. Childs Nerv Syst. 1999;15(2–3):87–9. Epub 7 May 1999.

    Article  PubMed  CAS  Google Scholar 

  26. Michelagnoli MP, Bailey CC, Wilson I, Livingston J, Kinsey SE. Potential salvage therapy for inadvertent intrathecal administration of vincristine. Br J Haematol. 1997;99(2):364–7. Epub 31 Dec 1997.

    Article  PubMed  CAS  Google Scholar 

  27. Thakur JS, Chauhan CG, Diwana VK, Chauhan DC, Thakur A. Extravasational side effects of cytotoxic drugs: a preventable catastrophe. Indian J Plast Surg. 2008;41(2):145–50. Epub 1 July 2008.

    Article  PubMed  Google Scholar 

  28. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther. 2003;3(2):263–76. Epub 29 Mar 2003.

    Article  PubMed  CAS  Google Scholar 

  29. Garfield DH, Hercbergs A. Fewer dollars, more sense. J Clin Oncol. 2008;26(32):5304–5; author reply 5. Epub 16 Oct 2008.

    Article  PubMed  Google Scholar 

  30. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108(9):3749–54. Epub 16 Feb 2011.

    Article  PubMed  CAS  Google Scholar 

  31. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31. Epub 3 Mar 2009.

    Article  PubMed  CAS  Google Scholar 

  32. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56(6):1131–6. Epub 20 Oct 2010.

    Article  PubMed  CAS  Google Scholar 

  33. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687–91. Epub 12 Oct 2011.

    Article  PubMed  Google Scholar 

  34. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40. Epub 2 Sept 2009.

    Article  PubMed  CAS  Google Scholar 

  35. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer. 2011;10(3):151–6. Epub 23 Aug 2011.

    Article  PubMed  CAS  Google Scholar 

  36. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46(2):439–48. Epub 17 Dec 2009.

    Article  PubMed  CAS  Google Scholar 

  37. Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106(4):601–8. Epub 17 Apr 2007.

    Article  PubMed  Google Scholar 

  38. Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzen F, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757–64. Epub 23 Mar 2011.

    Article  PubMed  CAS  Google Scholar 

  39. Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012;106(1):121–5. Epub 28 June 2011.

    Article  PubMed  CAS  Google Scholar 

  40. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–9. Epub 18 Feb 2012.

    Article  PubMed  CAS  Google Scholar 

  41. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487–94. Epub 3 Feb 2011.

    Article  PubMed  CAS  Google Scholar 

  42. Hompes D, Ruers T. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol. 2011;37(9):737–46. Epub 19 July 2011.

    Article  PubMed  CAS  Google Scholar 

  43. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011;114(6):1609–16. Epub 15 Dec 2010.

    Article  PubMed  Google Scholar 

  44. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559–68. Epub 2 June 2009.

    Article  PubMed  CAS  Google Scholar 

  45. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol. 2011;29(18):e560–2. Epub 25 May 2011.

    Article  PubMed  Google Scholar 

  46. Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, et al. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011;29(28):e739–42. Epub 9 Sept 2011.

    Article  PubMed  Google Scholar 

  47. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990;8(11):1907–12. Epub 1 Nov 1990.

    PubMed  CAS  Google Scholar 

  48. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 1997;57(10):1934–8. Epub 15 May 1997.

    PubMed  CAS  Google Scholar 

  49. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11(1):80–91. Epub 12 Sept 2008.

    Article  PubMed  CAS  Google Scholar 

  50. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7. Epub 1 Apr 2000.

    Article  PubMed  CAS  Google Scholar 

  51. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9. Epub 20 Oct 2007.

    Article  PubMed  CAS  Google Scholar 

  52. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995;13(1):210–21. Epub 1 Jan 1995.

    PubMed  CAS  Google Scholar 

  53. Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogi I, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998;16(2):692–701. Epub 20 Feb 1998.

    PubMed  CAS  Google Scholar 

  54. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol. 2005;23(30):7621–31. Epub 20 Oct 2005.

    Article  PubMed  Google Scholar 

  55. Kiefer T, Hirt C, Spath C, Schuler F, Al-Ali HK, Wolf HH, et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol. 2012;23(7):1809–12. Epub 24 Nov 2011.

    Article  PubMed  CAS  Google Scholar 

  56. Graber JJ, Omuro A. Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate? CNS Drugs. 2011;25(6):447–57. Epub 9 June 2011.

    Article  PubMed  CAS  Google Scholar 

  57. Yasuda K, Taguchi H, Sawamura Y, Ikeda J, Aoyama H, Fujieda K, et al. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system. Jpn J Clin Oncol. 2008;38(7):486–92. Epub 25 June 2008.

    Article  PubMed  Google Scholar 

  58. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007;19(2):108–14. Epub 16 Mar 2007.

    Article  CAS  Google Scholar 

  59. Groves MD. Leptomeningeal disease. Neurosurg Clin N Am. 2011;22(1):67–78, vii. Epub 27 Nov 2010.

    Article  PubMed  Google Scholar 

  60. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40(18):2726–33. Epub 2 Dec 2004.

    Article  PubMed  CAS  Google Scholar 

  61. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol. 1993;50(3):261–4. Epub 1 Mar 1993.

    Article  PubMed  CAS  Google Scholar 

  62. Dunton SF, Nitschke R, Spruce WE, Bodensteiner J, Krous HF. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study. Cancer. 1986;57(6):1083–8. Epub 15 Mar 1986.

    Article  PubMed  CAS  Google Scholar 

  63. Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992;10(6):948–53. Epub 1 June 1992.

    PubMed  CAS  Google Scholar 

  64. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36–51. Epub 1 Jan 1978.

    Article  PubMed  CAS  Google Scholar 

  65. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–9. Epub 6 Jan 2000.

    Article  PubMed  CAS  Google Scholar 

  66. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10(10):1579–91. Epub 1 Jan 1992.

    PubMed  CAS  Google Scholar 

  67. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010;21(11):2183–7. Epub 1 May 2010.

    Article  PubMed  CAS  Google Scholar 

  68. Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA. Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther. 1983;33(1):44–51. Epub 1 Jan 1983.

    Article  PubMed  CAS  Google Scholar 

  69. Berg SL, Poplack DG. Advances in the treatment of meningeal ­cancers. Crit Rev Oncol Hematol. 1995;20(1–2):87–98. Epub 1 Aug 1995.

    Article  PubMed  CAS  Google Scholar 

  70. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233–42. Epub 15 June 2011.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Centre Médico-Chirugical de la Broye, Payerne, Switzerland

    Miriame Mino M.D.

  2. Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    Krisztian Homicsko M.D., Ph.D.

  3. Departments of Neurosurgery and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

    Roger Stupp M.D.

Authors
  1. Miriame Mino M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Krisztian Homicsko M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roger Stupp M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Stupp M.D. .

Editor information

Editors and Affiliations

  1. , Department of Hematology-Oncology, Centre Hospitalier de Luxembourg, Rue Barble 4, Luxembourg, 1210, Luxembourg

    Mario A. Dicato

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Mino, M., Homicsko, K., Stupp, R. (2013). Central Nervous System. In: Dicato, M. (eds) Side Effects of Medical Cancer Therapy. Springer, London. https://doi.org/10.1007/978-0-85729-787-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-787-7_7

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-786-0

  • Online ISBN: 978-0-85729-787-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation